Zhong Yuejiao, Fan Qingyu, Zhou Zhaofei, Wang Yajing, He Kang, Lu Jianwei
Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Xuzhou Medical University Graduate School, Xuzhou, People's Republic of China.
Cancer Manag Res. 2020 May 5;12:3099-3106. doi: 10.2147/CMAR.S243320. eCollection 2020.
To investigate the clinical value of plasma cell-free DNA (cfDNA) as a potential biomarker for advanced gastric cancer (GC).
One hundred and six cases of advanced gastric cancer patients receiving chemotherapy were selected as study objects. Another 40 healthy volunteers were included as control groups. Plasma cfDNA concentration was detected by (SuperbDNA) hybridization. Changes in cfDNA concentration during chemotherapy in patients with gastric cancer whose efficacy was assessed as partial response (PR), stable disease (SD) and disease progression (PD) were analyzed respectively. The relationship between the level of cfDNA and the efficacy of chemotherapy and clinical characteristics was also explored. In addition, cfDNA and other tumor markers were subjected to specificity and sensitivity analyses using ROC.
cfDNA concentration in advanced GC patients was significantly higher than that in healthy controls (P<0.05). The concentration of plasma cfDNA in patients with PD showed an increasing trend over time. The concentration of plasma cfDNA in patients with therapeutic effect of PR decreased over time. In patients with therapeutic effect of SD, the plasma DNA concentration showed a stable trend over time. There was no significant correlation between cfDNA concentration and factors including gender, age, pathological type, CA724, CA125,CA199, AFP and CEA. ROC results showed that the area under the curve of cfDNA was larger than other tumor markers.
Plasma cfDNA concentration was significantly increased in patients with gastric cancer, and its diagnostic efficacy was superior to that of traditional tumor markers. It can be used as a tumor biomarker to monitor the efficacy of chemotherapy for gastric cancer.
探讨血浆游离DNA（cfDNA）作为晚期胃癌（GC）潜在生物标志物的临床价值。
选取106例接受化疗的晚期胃癌患者作为研究对象。另纳入40名健康志愿者作为对照组。采用（SuperbDNA）杂交法检测血浆cfDNA浓度。分别分析疗效评估为部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）的胃癌患者化疗期间cfDNA浓度的变化。还探讨了cfDNA水平与化疗疗效及临床特征之间的关系。此外，使用ROC对cfDNA和其他肿瘤标志物进行特异性和敏感性分析。
晚期GC患者的cfDNA浓度显著高于健康对照组（P<0.05）。PD患者的血浆cfDNA浓度随时间呈上升趋势。PR治疗效果患者的血浆cfDNA浓度随时间下降。SD治疗效果患者的血浆DNA浓度随时间呈稳定趋势。cfDNA浓度与性别、年龄、病理类型、CA724、CA125、CA199、AFP和CEA等因素之间无显著相关性。ROC结果显示，cfDNA的曲线下面积大于其他肿瘤标志物。
胃癌患者血浆cfDNA浓度显著升高，其诊断效能优于传统肿瘤标志物。它可作为一种肿瘤生物标志物来监测胃癌化疗疗效。
